Small-Caps Rushing to Fill the NASH Treatment Pipeline

Source:   ()
NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials. read more >

Innovative Company Focused on Women's Health Completes Record-Breaking Quarter

Source:   ()
Viveve Medical's Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts. read more >

Big Pharma Sets Its Sights on NASH Epidemic

Source:   ()
Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, organized the recent inaugural NASH Investor Conference. In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments. read more >

Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

Source:   ()
In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program. read more >
Management Q&A: View from the Top

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance

Managment Q&A: View from the Top
Source:   ()
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. read more >

DURECT and Sandoz Ink $293 Million Deal for POSIMIR

Source:   ()
DURECT Corp. and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for the U.S. for POSIMIR. read more >
Management Q&A: View from the Top

3D Signatures' Platform Taps into the Power of the Genome

Managment Q&A: View from the Top
Source:   ()
How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment. read more >
Expert Investing Ideas

"SNSS' SNS-062 Phase Ib/II is expected to begin in H1/17."

–Maxim Jacobs, Edison Investment Research


"We continue to be optimistic about DRRX's story."

–Grant Zeng, Zacks Equity Research


NASDAQ Biotech ARCA Pharmaceutical
Management Q&A: View from the Top

The ProMIS of an Alzheimer's Cure

Managment Q&A: View from the Top
Source:   ()
With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report. read more >

Mesoblast Heart Failure Trial Delivers Positive Interim Results

Source:   ()
Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress. read more >

Good Epilepsy Data from Zynerba Pharmaceuticals Would Set Stage for Pivotal Trials

Source:   ()
Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials. read more >

Trial Results Set Up DURECT Corp. for 'Exciting Year'

Source:   ()
Positive results in a Phase 1b trial of DURECT Corp.'s candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of analysts. read more >
Biotech Watchlist 2017